Octreotide

DCTPepD ID  DCTPepD0003

Active Ingredients   Octreotide

Description  A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.

Synonyms  SMS-201-995; D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2->7)-Disulfide; Octreotide

Disease  Acromegaly, Diarrhea, Metastatic Carcinoid Tumors

Classification

  

Somatostatin and analogues Peptide and derivative Cyclic

Structure Information


Molecular Formula  C49H66N10O10S2

Molecular Weight  1019.247

Active Sequence  FCFWKXCT

Sequence Length  8

Modification  X=xiThr, N-terminal ol

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

InChI  InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29?,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

InChI_Key DEQANNDTNATYII-RRCPSWKPSA-N

SMILES  CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@H](CSSC[C@H](NC1=O)C(N[C@@H]([C@H](O)C)CO)=O)NC([C@@H](CC2=CC=CC=C2)N)=O)=O)CC3=CC=CC=C3)=O)CC4=CNC5=CC=CC=C45)=O)CCCCN)=O)O

External Codes


PubChem CID  6400441

DrugBank Accession Number  DB00104

NCI Thesaurus Code  C711  

UNII  RWM8CCW8GP   GSRS

CAS  83150-76-9



Drug approval


Drug indication
    Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Octreotide Acetate eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Teva Pharms Usa Prescription ANDA: 075957 2005
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Teva Pharms Usa Prescription ANDA: 075959 2005
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection West-Ward Pharms Int Prescription ANDA: 076330 2005
Octreotide Acetate eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Sun Pharm Inds Discontinued ANDA: 077329 2008
Octreotide Acetate eq 0.2mg base/ml Injectable; Injection Sun Pharm Inds Discontinued ANDA: 077330 2008
Octreotide Acetate eq 1mg base/ml Injectable; Injection Sun Pharm Inds Discontinued ANDA: 077331 2008
Octreotide Acetate eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Sun Pharm Inds Prescription ANDA: 077372 2007
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Sun Pharm Inds Prescription ANDA: 077373 2007
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Fresenius Kabi Usa Prescription ANDA: 077450 2006
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Wockhardt Usa Discontinued ANDA: 090986 2011
Octreotide Acetate eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Sagent Pharms Prescription ANDA: 091041 2013
Octreotide Acetate (Preservative Free) eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection West-Ward Pharms Int Prescription ANDA: 076313 2005
Octreotide Acetate (Preservative Free) eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Fresenius Kabi Usa Prescription ANDA: 077457 2006
Octreotide Acetate (Preservative Free) eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Mylan Institutional Prescription ANDA: 079198 2011
Octreotide Acetate (Preservative Free) eq 0.05mg base/ml; eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Sagent Pharms Prescription ANDA: 090834 2013
Octreotide Acetate Preservative Free eq 0.05mg base/ml;eq 0.1mg base/ml; eq 0.5mg base/ml Injectable; Injection Wockhardt Usa Discontinued ANDA: 090985 2011
Sandostatin eq 0.05mg base/ml;eq 0.1mg base/ml; eq 0.5mg base/ml; eq 0.2mg base/ml; eq 1mg base/ml Injectable; Injection Novartis Prescription NDA: 019667 1988
Sandostatin Lar eq 10mg base/vial; eq 20mg base/vial; eq 30mg base/vial Injectable; Injection Novartis Prescription NDA: 021008 1998
Ocphyl 50 mcg/ml Injectable; Injection Pendopharm Division Of De Pharmascience Inc Prescription DIN: 02413191 2014
Ocphyl 100 mcg/ml Injectable; Injection Pendopharm Division Of De Pharmascience Inc Prescription DIN: 02413205 2014
Ocphyl 500 mcg/ml Injectable; Injection Pendopharm Division Of De Pharmascience Inc Prescription DIN: 02413213 2014
Octreotide Acetate Injection - 100Mcg/Ml 100 mcg/ml Injectable; Injection Sandoz Canada Incorporated Prescription DIN: 02263173 2005
Octreotide Acetate Injection - 200Mcg/Ml 200 mcg/ml Injectable; Injection Sandoz Canada Incorporated Prescription DIN: 02263181 2005
Octreotide Acetate Injection - 500Mcg/Ml 500 mcg/ml Injectable; Injection Sandoz Canada Incorporated Prescription DIN: 02263203 2005
Octreotide Acetate Injection - 50Mcg/Ml 50 mcg/ml Injectable; Injection Sandoz Canada Incorporated Prescription DIN: 02263165 2005
Octreotide Acetate Omega 100Mcg/Ml 100 mcg/ml Injectable; Injection Omega Laboratories Ltd Prescription DIN: 02248640 2004
Octreotide Acetate Omega 200Mcg/Ml 200 mcg/ml Injectable; Injection Omega Laboratories Ltd Prescription DIN: 02248642 2004
Octreotide Acetate Omega 500Mcg/Ml 500 mcg/ml Injectable; Injection Omega Laboratories Ltd Prescription DIN: 02248641 2004
Octreotide Acetate Omega 50Mcg/Ml 50 mcg/ml Injectable; Injection Omega Laboratories Ltd Prescription DIN: 02248639 2004
Octreotide Injection 50 mcg/ml Injectable; Injection Teva Canada Limited Prescription DIN: 02299429 2014
Octreotide Injection 100 mcg/ml Injectable; Injection Teva Canada Limited Prescription DIN: 02299437 2008
Octreotide Injection 200 mcg/ml Injectable; Injection Teva Canada Limited Prescription DIN: 02299445 2008
Octreotide Injection 500 mcg/ml Injectable; Injection Teva Canada Limited Prescription DIN: 02299453 2008
Sandostatin 100Mcg/Ml 100 mcg/ml Injectable; Injection Novartis Pharmaceuticals Canada Inc Prescription DIN: 00839205 1989
Sandostatin 200Mcg/Ml 200 mcg/ml Injectable; Injection Novartis Pharmaceuticals Canada Inc Prescription DIN: 02049392 1996
Sandostatin 500Mcg/Ml 500 mcg/ml Injectable; Injection Novartis Pharmaceuticals Canada Inc Prescription DIN: 00839213 1989
Sandostatin 50Mcg/Ml 50 mcg/ml Injectable; Injection Novartis Pharmaceuticals Canada Inc Prescription DIN: 00839191 1989
Sandostatin Lar 10Mg 10 mcg/vial Powder; Intramuscular Novartis Pharmaceuticals Canada Inc Prescription DIN: 02239323 1999
Sandostatin Lar 20Mg 20 mcg/vial Powder; Intramuscular Novartis Pharmaceuticals Canada Inc Prescription DIN: 02239324 1999
Sandostatin Lar 30Mg 30 mcg/vial Powder; Intramuscular Novartis Pharmaceuticals Canada Inc Prescription DIN: 02239325 1999
Sandostatin 1 ml: 0.1 mg Injectable; Injection Novartis Pharma Schweiz Ag Prescription NMPA: H20150364 1996

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT03289741 A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors Neuroendocrine Tumors Phase 4 Treatment
NCT02409849 Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas Gastro-entero-pancreatic Carcinoma; Esophageal Neuroendocrine Carcinoma Phase 2 Treatment
NCT05459844 A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours Neuroendocrine Tumors Phase 3 Treatment
NCT01578239 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour Phase 3 Treatment
NCT00427349 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.